ACAD vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACAD demonstrates strong financial health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and profitability. The company trades below its Graham Number ($19.31) and intrinsic value estimate ($67.85), suggesting potential undervaluation on a defensive basis. However, recent earnings growth has reversed sharply, with year-over-year EPS declining by 83.7% and Q/Q growth at -66.7%, raising concerns about sustainability. Insider selling activity over the past six months, totaling $1.17M, adds bearish sentiment despite the strong F-Score. Analysts remain optimistic with a buy recommendation and a target price of $31.85, but the current price is still significantly below intrinsic value.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ACAD vs LLY: Head-to-Head Comparison
This page compares ACADIA Pharmaceuticals Inc. (ACAD) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.